Advanced search
Publication Cover
Pharmacogenomics Volume 14, 2013 - Issue 8
Submit an article Journal homepage
410
Views
0
CrossRef citations to date
0
Altmetric
Review

Pharmacogenomics of Lipid-Lowering Therapies

Miao Hu1 Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong SARView further author information
&
Brian Tomlinson1 Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong SARCorrespondence[email protected]
View further author information
Pages 981-995 | Published online: 07 Jun 2013

References

  • Singh IM , ShishehborMH, AnsellBJ. High-density lipoprotein as a therapeutic target: a systematic review. JAMA298(7) , 786–798 (2007).
  • Sarwar N , SandhuMS, RickettsSL et al. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet 375(9726) , 1634–1639 (2010).
  • Nordestgaard BG , ChapmanMJ, RayK et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur. Heart J. 31(23) , 2844–2853 (2010).
  • Voight BF , PelosoGM, Orho-MelanderM et al. Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study. Lancet 380(9841) , 572–580 (2012).
  • Baigent C , BlackwellL, EmbersonJ et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376(9753) , 1670–1681 (2010).
  • Baigent C , KeechA, KearneyPM et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366(9493) , 1267–1278 (2005).
  • Mihaylova B , EmbersonJ, BlackwellL et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 380(9841) , 581–590 (2012).
  • Mihos CG , SalasMJ, SantanaO. The pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in cardiovascular disease: a comprehensive review. Cardiol. Rev.18(6) , 298–304 (2010).
  • Hu M , MakVWL, ChuTTY, WayeMMY, TomlinsonB. Pharmacogenetics of HMG-CoA reductase inhibitors: optimizing the prevention of coronary heart disease. Curr. Pharmacogenomics Pers. Med.7(1) , 1–26 (2009).
  • Sirtori CR , MombelliG, TrioloM, LaaksonenR. Clinical response to statins: mechanism(s) of variable activity and adverse effects. Ann. Med.44(5) , 419–432 (2012).
  • Postmus I , VerschurenJJ, De Craen AJ et al. Pharmacogenetics of statins: achievements, whole-genome analyses and future perspectives. Pharmacogenomics13(7) , 831–840 (2012).
  • Mangravite LM , ThornCF, KraussRM. Clinical implications of pharmacogenomics of statin treatment. Pharmacogenomics J.6(6) , 360–374 (2006).
  • Neuvonen PJ , NiemiM, BackmanJT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin. Pharmacol. Ther.80(6) , 565–581 (2006).
  • Neuvonen PJ , BackmanJT, NiemiM. Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin. Clin. Pharmacokinet.47(7) , 463–474 (2008).
  • Elsby R , HilgendorfC, FennerK. Understanding the critical disposition pathways of statins to assess drug–drug interaction risk during drug development: it‘s not just about OATP1B1. Clin. Pharmacol. Ther.92(5) , 584–598 (2012).
  • Hu M , MakVW, XiaoY, TomlinsonB. Associations between the genotypes and phenotype of CYP3A and the lipid response to simvastatin in Chinese patients with hypercholesterolemia. Pharmacogenomics14(1) , 25–34 (2013).
  • Wang D , GuoY, WrightonSA, CookeGE, SadeeW. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J.11(4) , 274–286 (2011).
  • Elens L , BeckerML, HaufroidV et al. Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study. Pharmacogenet. Genomics 21(12) , 861–866 (2011).
  • Romaine SP , BaileyKM, HallAS, BalmforthAJ. The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy. Pharmacogenomics J.10(1) , 1–11 (2010).
  • Hu M , ToKK, MakVW, TomlinsonB. The ABCG2 transporter and its relations with the pharmacokinetics, drug interaction and lipid-lowering effects of statins. Expert Opin. Drug Metab. Toxicol.7(1) , 49–62 (2011).
  • Rodrigues AC . Efflux and uptake transporters as determinants of statin response. Expert Opin. Drug Metab. Toxicol.6(5) , 621–632 (2010).
  • Niemi M , PasanenMK, NeuvonenPJ. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol. Rev.63(1) , 157–181 (2011).
  • Nezasa K , HigakiK, MatsumuraT et al. Liver-specific distribution of rosuvastatin in rats: comparison with pravastatin and simvastatin. Drug Metab. Dispos. 30(11) , 1158–1163 (2002).
  • Niemi M . Transporter pharmacogenetics and statin toxicity. Clin. Pharmacol. Ther.87(1) , 130–133 (2010).
  • Link E , ParishS, ArmitageJ et al. SLCO1B1 variants and statin-induced myopathy – a genomewide study. N. Engl. J. Med. 359(8) , 789–799 (2008).
  • Donnelly LA , DoneyAS, TavendaleR et al. Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with Type 2 diabetes: a go-DARTS study. Clin. Pharmacol. Ther. 89(2) , 210–216 (2011).
  • Voora D , ShahSH, SpasojevicI et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J. Am. Coll. Cardiol. 54(17) , 1609–1616 (2009).
  • Elhayany A , MishaalRA, VinkerS. Is there clinical benefit to routine enzyme testing of patients on statins? Expert Opin. Drug Saf.11(2) , 185–190 (2012).
  • Brunham LR , LansbergPJ, ZhangL et al. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. Pharmacogenomics J. 12(3) , 233–237 (2012).
  • Santos PC , GagliardiAC, MinameMH et al. SLCO1B1 haplotypes are not associated with atorvastatin-induced myalgia in Brazilian patients with familial hypercholesterolemia. Eur. J. Clin. Pharmacol.68(3) , 273–279 (2012).
  • Keskitalo JE , PasanenMK, NeuvonenPJ, NiemiM. Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin. Pharmacogenomics10(10) , 1617–1624 (2009).
  • Keskitalo JE , ZolkO, FrommMF, KurkinenKJ, NeuvonenPJ, NiemiM. ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin. Pharmacol. Ther.86(2) , 197–203 (2009).
  • Hu M , LuiSS, MakVW et al. Pharmacogenetic analysis of lipid responses to rosuvastatin in Chinese patients. Pharmacogenet. Genomics 20(10) , 634–637 (2010).
  • Tomlinson B , HuM, LeeVW et al. ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin. Clin. Pharmacol. Ther.87(5) , 558–562 (2010).
  • Bailey KM , RomaineSP, JacksonBM et al. Hepatic metabolism and transporter gene variants enhance response to rosuvastatin in patients with acute myocardial infarction: the GEOSTAT-1 Study. Circ. Cardiovasc. Genet. 3(3) , 276–285 (2010).
  • Zhang W , YuBN, HeYJ et al. Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. Clin. Chim. Acta 373(1–2) , 99–103 (2006).
  • Chasman DI , PosadaD, SubrahmanyanL, CookNR, StantonVP Jr, Ridker PM. Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA291(23) , 2821–2827 (2004).
  • Krauss RM , MangraviteLM, SmithJD et al. Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment. Circulation 117(12) , 1537–1544 (2008).
  • Thompson JF , HydeCL, WoodLS et al. Comprehensive whole-genome and candidate gene analysis for response to statin therapy in the Treating to New Targets (TNT) cohort. Circ. Cardiovasc. Genet. 2(2) , 173–181 (2009).
  • Singer JB , HoldaasH, JardineAG et al. Genetic analysis of fluvastatin response and dyslipidemia in renal transplant recipients. J. Lipid Res. 48(9) , 2072–2078 (2007).
  • Polisecki E , MuallemH, MaedaN et al. Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER. Atherosclerosis 200(1) , 109–114 (2008).
  • Yamamoto A , KamiyaT, YamamuraT et al. Clinical features of familial hypercholesterolemia. Arteriosclerosis 9(Suppl. 1) , I66–I74 (1989).
  • Couture P , BrunLD, SzotsF et al. Association of specific LDL receptor gene mutations with differential plasma lipoprotein response to simvastatin in young French Canadians with heterozygous familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 18(6) , 1007–1012 (1998).
  • Miltiadous G , XenophontosS, BairaktariE, GanotakisM, CariolouM, ElisafM. Genetic and environmental factors affecting the response to statin therapy in patients with molecularly defined familial hypercholesterolaemia. Pharmacogenet. Genomics15(4) , 219–225 (2005).
  • Kajinami K , YagiK, HigashikataT, InazuA, KoizumiJ, MabuchiH. Low-density lipoprotein receptor genotype-dependent response to cholesterol lowering by combined pravastatin and cholestyramine in familial hypercholesterolemia. Am. J. Cardiol.82(1) , 113–117 (1998).
  • Thompson JF , ManM, JohnsonKJ et al. An association study of 43 SNPs in 16 candidate genes with atorvastatin response. Pharmacogenomics J. 5(6) , 352–358 (2005).
  • Mousavi SA , BergeKE, LerenTP. The unique role of proprotein convertase subtilisin/kexin 9 in cholesterol homeostasis. J. Intern. Med.266(6) , 507–519 (2009).
  • Abifadel M , RabesJP, DevillersM et al. Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease. Hum. Mutat. 30(4) , 520–529 (2009).
  • Soutar AK , NaoumovaRP. Mechanisms of disease: genetic causes of familial hypercholesterolemia. Nat. Clin. Pract. Cardiovasc. Med.4(4) , 214–225 (2007).
  • Konrad RJ , TrouttJS, CaoG. Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents. Lipids Health Dis.10 , 38 (2011).
  • Naoumova RP , TosiI, PatelD et al. Severe hypercholesterolemia in four British families with the D374Y mutation in the PCSK9 gene: long-term follow-up and treatment response. Arterioscler. Thromb. Vasc. Biol. 25(12) , 2654–2660 (2005).
  • Pisciotta L , SalloR, RabacchiC, WunschA, CalandraS, BertoliniS. Leucine 10 allelic variant in signal peptide of PCSK9 increases the LDL cholesterol-lowering effect of statins in patients with familial hypercholesterolaemia. Nutr. Metab. Cardiovasc. Dis.22(10) , 831–835 (2012).
  • Chen SN , BallantyneCM, GottoAM Jr, Tan Y, Willerson JT, Marian AJ. A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis. J. Am. Coll. Cardiol.45(10) , 1611–1619 (2005).
  • Norata GD , GarlaschelliK, GrigoreL et al. Effects of PCSK9 variants on common carotid artery intima media thickness and relation to ApoE alleles. Atherosclerosis 208(1) , 177–182 (2010).
  • Kotowski IK , PertsemlidisA, LukeA et al. A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol. Am. J. Hum. Genet. 78(3) , 410–422 (2006).
  • Peters BJ , PettH, KlungelOH et al. Genetic variability within the cholesterol lowering pathway and the effectiveness of statins in reducing the risk of MI. Atherosclerosis 217(2) , 458–464 (2011).
  • Nieminen T , KahonenM, ViiriLE, GronroosP, LehtimakiT. Pharmacogenetics of apolipoprotein E gene during lipid-lowering therapy: lipid levels and prevention of coronary heart disease. Pharmacogenomics9(10) , 1475–1486 (2008).
  • Voora D , ShahSH, ReedCR et al. Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response. Circ. Cardiovasc. Genet. 1(2) , 100–106 (2008).
  • Mega JL , MorrowDA, BrownA, CannonCP, SabatineMS. Identification of genetic variants associated with response to statin therapy. Arterioscler. Thromb. Vasc. Biol.29(9) , 1310–1315 (2009).
  • Gerdes LU , GerdesC, KervinenK et al. The apolipoprotein ε4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction: a substudy of the Scandinavian simvastatin survival study. Circulation 101(12) , 1366–1371 (2000).
  • Chiodini BD , FranzosiMG, BarleraS et al. Apolipoprotein E polymorphisms influence effect of pravastatin on survival after myocardial infarction in a Mediterranean population: the GISSI-Prevenzione study. Eur. Heart J. 28(16) , 1977–1983 (2007).
  • Schnapp BJ . Trafficking of signaling modules by kinesin motors. J. Cell Sci.116(Pt 11) , 2125–2135 (2003).
  • Morrison AC , BareLA, ChamblessLE et al. Prediction of coronary heart disease risk using a genetic risk score: the atherosclerosis risk in communities study. Am. J. Epidemiol. 166(1) , 28–35 (2007).
  • Shiffman D , ChasmanDI, ZeeRY et al. A kinesin family member 6 variant is associated with coronary heart disease in the Women‘s Health Study. J. Am. Coll. Cardiol. 51(4) , 444–448 (2008).
  • Iakoubova OA , SabatineMS, RowlandCM et al. Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study. J. Am. Coll. Cardiol. 51(4) , 449–455 (2008).
  • Iakoubova OA , TongCH, RowlandCM et al. Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials. J. Am. Coll. Cardiol. 51(4) , 435–443 (2008).
  • Assimes TL , HolmH, KathiresanS et al. Lack of association between the Trp719Arg polymorphism in kinesin-like protein-6 and coronary artery disease in 19 case–control studies. J. Am. Coll. Cardiol. 56(19) , 1552–1563 (2010).
  • Hoffmann MM , MarzW, GenserB, DrechslerC, WannerC. Lack of association between the Trp719Arg polymorphism in kinesin-like protein-6 and cardiovascular risk and efficacy of atorvastatin among subjects with diabetes on dialysis: the 4D study. Atherosclerosis219(2) , 659–662 (2011).
  • Ridker PM , MacFadyenJG, GlynnRJ, ChasmanDI. Kinesin-like protein 6 (KIF6) polymorphism and the efficacy of rosuvastatin in primary prevention. Circ. Cardiovasc. Genet.4(3) , 312–317 (2011).
  • Hopewell JC , ParishS, ClarkeR et al. No impact of KIF6 genotype on vascular risk and statin response among 18,348 randomized patients in the heart protection study. J. Am. Coll. Cardiol. 57(20) , 2000–2007 (2011).
  • Arsenault BJ , BoekholdtSM, HovinghGK et al. The 719Arg variant of KIF6 and cardiovascular outcomes in statin-treated, stable coronary patients of the treating to new targets and incremental decrease in end points through aggressive lipid-lowering prospective studies. Circ. Cardiovasc. Genet. 5(1) , 51–57 (2012).
  • Marciante KD , DurdaJP, HeckbertSR et al. Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenet. Genomics 21(5) , 280–288 (2011).
  • Isackson PJ , Ochs-BalcomHM, MaC et al. Association of common variants in the human eyes shut ortholog (EYS) with statin-induced myopathy: evidence for additional functions of EYS. Muscle Nerve 44(4) , 531–538 (2011).
  • Chasman DI , GiulianiniF, MacFadyenJ, BarrattBJ, NybergF, RidkerPM. Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial. Circ. Cardiovasc. Genet.5(2) , 257–264 (2012).
  • Deshmukh HA , ColhounHM, JohnsonT et al. Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a). J. Lipid Res. 53(5) , 1000–1011 (2012).
  • Hopewell JC , ParishS, OfferA et al. Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study. Eur. Heart J. 34(13) , 982–992 (2012).
  • Barber MJ , MangraviteLM, HydeCL et al. Genome-wide association of lipid-lowering response to statins in combined study populations. PLoS ONE 5(3) , e9763 (2010).
  • Chu AY , GuilianiniF, BarrattBJ, NybergF, ChasmanDI, RidkerPM. Pharmacogenetic determinants of statin-induced reductions in C-reactive protein. Circ. Cardiovasc. Genet.5(1) , 58–65 (2012).
  • Thompson A , GaoP, OrfeiL et al. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 375(9725) , 1536–1544 (2010).
  • Chu AY , GuilianiniF, GrallertH et al. Genome-wide association study evaluating lipoprotein-associated phospholipase A2 mass and activity at baseline and after rosuvastatin therapy. Circ. Cardiovasc. Genet. 5(6) , 676–685 (2012).
  • Shiffman D , TrompetS, LouieJZ et al. Genome-wide study of gene variants associated with differential cardiovascular event reduction by pravastatin therapy. PLoS ONE 7(5) , e38240 (2012).
  • Phan BA , DayspringTD, TothPP. Ezetimibe therapy: mechanism of action and clinical update. Vasc. Health Risk Manag.8 , 415–427 (2012).
  • Leiter LA , BetteridgeDJ, FarnierM et al. Lipid-altering efficacy and safety profile of combination therapy with ezetimibe/statin vs. statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trials. Diabetes Obes. Metab. 13(7) , 615–628 (2011).
  • Lioudaki E , GanotakisES, MikhailidisDP. Ezetimibe; more than a low density lipoprotein cholesterol lowering drug? an update after 4 years. Curr. Vasc. Pharmacol.9(1) , 62–86 (2011).
  • Pisciotta L , FasanoT, BellocchioA et al. Effect of ezetimibe coadministered with statins in genotype-confirmed heterozygous FH patients. Atherosclerosis 194(2) , e116–e122 (2007).
  • Hegele RA , GuyJ, BanMR, WangJ. NPC1L1 haplotype is associated with inter-individual variation in plasma low-density lipoprotein response to ezetimibe. Lipids Health Dis.4 , 16 (2005).
  • Simon JS , KarnoubMC, DevlinDJ et al. Sequence variation in NPC1L1 and association with improved LDL-cholesterol lowering in response to ezetimibe treatment. Genomics 86(6) , 648–656 (2005).
  • Berthold HK , LaaksonenR, LehtimakiT, GyllingH, KroneW, Gouni-BertholdI. SREBP-1c gene polymorphism is associated with increased inhibition of cholesterol-absorption in response to ezetimibe treatment. Exp. Clin. Endocrinol. Diabetes116(5) , 262–267 (2008).
  • Chapman MJ , RedfernJS, McGovernME, GiralP. Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. Pharmacol. Ther.126(3) , 314–345 (2010).
  • Perez-Martinez P , CorellaD, ShenJ et al. Association between glucokinase regulatory protein (GCKR) and apolipoprotein A5 (APOA5) gene polymorphisms and triacylglycerol concentrations in fasting, postprandial, and fenofibrate-treated states. Am. J. Clin. Nutr. 89(1) , 391–399 (2009).
  • Cardona F , GuardiolaM, Queipo-OrtunoMI, MurriM, RibaltaJ, TinahonesFJ. The -1131T>C SNP of the APOA5 gene modulates response to fenofibrate treatment in patients with the metabolic syndrome: a postprandial study. Atherosclerosis206(1) , 148–152 (2009).
  • Lai CQ , ArnettDK, CorellaD et al. Fenofibrate effect on triglyceride and postprandial response of apolipoprotein A5 variants: the GOLDN study. Arterioscler. Thromb. Vasc. Biol. 27(6) , 1417–1425 (2007).
  • Smith JA , ArnettDK, KellyRJ et al. The genetic architecture of fasting plasma triglyceride response to fenofibrate treatment. Eur. J. Hum. Genet. 16(5) , 603–613 (2008).
  • Boden WE , ProbstfieldJL, AndersonT et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N. Engl. J. Med. 365(24) , 2255–2267 (2011).
  • Hu M , ChuWC, YamashitaS et al. Liver fat reduction with niacin is influenced by DGAT-2 polymorphisms in hypertriglyceridemic patients. J. Lipid Res. 53(4) , 802–809 (2012).
  • Brautbar A , CovarrubiasD, BelmontJ et al. Variants in the APOA5 gene region and the response to combination therapy with statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia. Atherosclerosis 219(2) , 737–742 (2011).
  • Brautbar A , ViraniSS, BelmontJ, NambiV, JonesPH, BallantyneCM. LPL gene variants affect apoC-III response to combination therapy of statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia. J. Lipid Res.53(3) , 556–560 (2012).
  • Wilke RA , RamseyLB, JohnsonSG et al. The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin. Pharmacol. Ther. 92(1) , 112–117 (2012).
  • Cordero P , AshleyEA. Whole-genome sequencing in personalized therapeutics. Clin. Pharmacol. Ther.91(6) , 1001–1009 (2012).
  • Liu Y , OrdovasJM, GaoG et al. Pharmacogenetic association of the APOA1/C3/A4/A5 gene cluster and lipid responses to fenofibrate: the genetics of lipid-lowering drugs and diet network study. Pharmacogenet. Genomics 19(2) , 161–169 (2009).
  • Wojczynski MK , GaoG, BoreckiI et al. Apolipoprotein B genetic variants modify the response to fenofibrate: a GOLDN study. J. Lipid Res. 51(11) , 3316–3323 (2010).
  • Irvin MR , KabagambeEK, TiwariHK et al. Apolipoprotein E polymorphisms and postprandial triglyceridemia before and after fenofibrate treatment in the Genetics of Lipid Lowering and Diet Network (GOLDN) Study. Circ. Cardiovasc. Genet. 3(5) , 462–467 (2010).
  • Christidis DS , LiberopoulosEN, KakafikaAI et al. The effect of apolipoprotein E polymorphism on the response to lipid-lowering treatment with atorvastatin or fenofibrate. J. Cardiovasc. Pharmacol. Ther. 11(3) , 211–221 (2006).
  • Brisson D , LedouxK, BosseY et al. Effect of apolipoprotein E, peroxisome proliferator-activated receptor α and lipoprotein lipase gene mutations on the ability of fenofibrate to improve lipid profiles and reach clinical guideline targets among hypertriglyceridemic patients. Pharmacogenetics 12(4) , 313–320 (2002).
  • Shen J , ArnettDK, ParnellLD et al. The effect of CYP7A1 polymorphisms on lipid responses to fenofibrate. J. Cardiovasc. Pharmacol. 59(3) , 254–259 (2012).
  • Brouillette C , BosseY, PerusseL, GaudetD, VohlMC. Effect of liver fatty acid binding protein (FABP) T94A missense mutation on plasma lipoprotein responsiveness to treatment with fenofibrate. J. Hum. Genet.49(8) , 424–432 (2004).
  • Chien KL , LinYL, WenHC et al. Common sequence variant in lipoprotein lipase gene conferring triglyceride response to fibrate treatment. Pharmacogenomics 10(2) , 267–276 (2009).
  • Liu Y , OrdovasJM, GaoG et al. The SCARB1 gene is associated with lipid response to dietary and pharmacological interventions. J. Hum. Genet. 53(8) , 709–717 (2008).
  • Foucher C , RattierS, FlavellDM et al. Response to micronized fenofibrate treatment is associated with the peroxisome-proliferator-activated receptors α G/C intron7 polymorphism in subjects with Type 2 diabetes. Pharmacogenetics 14(12) , 823–829 (2004).
  • Shen J , ArnettDK, ParnellLD et al. Association of common C-reactive protein (CRP) gene polymorphisms with baseline plasma CRP levels and fenofibrate response: the GOLDN study. Diabetes Care 31(5) , 910–915 (2008).
  • Aslibekyan S , KabagambeEK, IrvinMR et al. A genome-wide association study of inflammatory biomarker changes in response to fenofibrate treatment in the genetics of lipid lowering drug and diet network. Pharmacogenet. Genomics 22(3) , 191–197 (2012).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.